CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-15 | Veinrib Gadi Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Seehra Jasbir Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Rubin Steven D Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Pontifax Management III G.P. (2011) Ltd. 10% owner | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Pontifax Management III G.P. (2011) Ltd. 10% owner | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Nussbaum Ran Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Noiman Silvia Chief Executive Officer | Grant or award | +141,389 | 141,389 | ||
| 2018-06-15 | Noiman Silvia Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +141,389 | 141,389 | ||
| 2018-06-15 | Noiman Silvia Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Kleijwegt Martijn Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-15 | Kariv Tomer Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-06-06 | Noiman Silvia Chief Executive Officer | Option exercise | +349,400 | $0.00 | $210 | 490,789 |
| 2018-06-06 | Noiman Silvia Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −349,400 | 0 | ||
| 2018-05-22 | Ward Robert Chief Executive Officer | Purchase | +5,000 | $14.34 | $72K | 15,000 |
| 2018-05-16 | Huertas Pedro Chief Medical Officer | Grant or award | +33,000 | 137,725 | ||
| 2018-05-11 | Huertas Pedro Chief Medical Officer | Grant or award | +104,725 | 104,725 | ||
| 2018-05-10 | Huertas Pedro Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +104,725 | 104,725 | ||
| 2018-04-30 | Shabtai Gilad 10% owner | Purchase | +75,000 | $9.75 | $731K | 3,351,770 |
Page 14 of 20 · 388 trades